Groups blast Tufts' $2.6bn drug RnD cost analysis
This article was originally published in SRA
Executive Summary
Some groups were having trouble swallowing the $2.6bn figure US researchers from the drug industry-funded Tufts Center for the Study of Drug Development (CSDD) declared on 18 November as the cost of developing a new prescription medicine1,2.